Results 91 to 96 of about 694 (96)

Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval

Future Oncology, 2022
Khin Thway, Myles Smith, Andrea Napolitano   +2 more
exaly  

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

Oncologist, 2021
Sebastian Bauer, Patrick Schöffski, Jean-Yves Blay   +2 more
exaly  

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Cancer Cell, 2019
Albiruni Ryan Abdul Razak, Filip Janku, Ying Su   +2 more
exaly  

Inhibition of human UDP-glucuronosyltransferase enzyme by ripretinib: Implications for drug-drug interactions

Toxicology and Applied Pharmacology, 2023
exaly  

Ripretinib induced skeletal muscle toxicity through mitochondrial impairment in C2C12 myotubes

Toxicology, 2023
exaly  

Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China

European Journal of Cancer
Xuelong Jiao
exaly